Sotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) Book value per share
Sotera Health Company's book value per share at the end of fiscal 2025 was 2.1×, up 49.1% from 1.4× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 2.6×. Over the past ten years it has ranged from −2.8× (fiscal 2019) to 2.1× (fiscal 2025) — the current reading is the highest in ten years. Sotera Health Company ranks 28th of 49 Diagnostics & Research companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 2.1× | 49.05% |
| FY2024 | 1.4× | (9.32%) |
| FY2023 | 1.6× | 26.29% |
| FY2022 | 1.3× | (40.43%) |
| FY2021 | 2.1× | 9.76% |
| FY2020 | 1.9× | — |
| FY2019 | −2.8× | — |
| FY2018 | 0.2× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 2.6× | 10.07% |
| Jun 2026 | 2.3× | 6.60% |
| Mar 2026 | 2.2× | 2.38% |
| Dec 2025 | 2.1× | 10.14% |
| 26 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| GRAL GRAIL, Inc. compare | 52.5× |
| RDNT RadNet, Inc. compare | 17.9× |
| VCYT Veracyte, Inc. compare | 17.8× |
| QGEN QIAGEN N.V. compare | 16.3× |
| CDNA CareDx, Inc. compare | 9.0× |
| NEO NeoGenomics, Inc. compare | 6.2× |
| SHC Sotera Health Company | 2.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 1.1× |
| BLLN BillionToOne, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement